Evidence map›Paper›PMID 42179100›Full record

ArticleAngewandte Chemie (International ed. in English)2026

Total Chemical Synthesis of Interleukin-15 and Interleukin-2: Taming Protein Hydrophobicity and Aggregation by a Versatile Solubilizing Strategy.

Jingwen Zeng, Haiyan Zhou, Wang Xia, Hongxiang Wu, Xuechen Li

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jingwen ZengDepartment of Chemistry, State Key Laboratory of Synthetic Chemistry, The University of Hong Kong, Hong Kong, SAR, P. R. China.
Haiyan ZhouDepartment of Chemistry, State Key Laboratory of Synthetic Chemistry, The University of Hong Kong, Hong Kong, SAR, P. R. China.
Wang XiaDepartment of Chemistry, State Key Laboratory of Synthetic Chemistry, The University of Hong Kong, Hong Kong, SAR, P. R. China.
Hongxiang WuDepartment of Chemistry, State Key Laboratory of Synthetic Chemistry, The University of Hong Kong, Hong Kong, SAR, P. R. China.
Xuechen LiDepartment of Chemistry, State Key Laboratory of Synthetic Chemistry, The University of Hong Kong, Hong Kong, SAR, P. R. China.ORCID 0000-0001-5465-7727

Funding

Research Grants Council of Hong Kong 17303424Research Grants Council of Hong Kong 17312022Research Grants Council of Hong Kong SRFS2324-7S01Research Grants Council of Hong Kong T11-104/22-R
6 · The paper itself

Abstract

Hydrophobic and aggregation-prone proteins still present obstacles for protein chemical synthesis and engineering. The chemical synthesis of Interleukin-15 (IL-15) is a formidable challenge due to inherent sequence hydrophobicity and severe peptide aggregation, which impedes downstream protein engineering and chemical biology studies. Here, we report the first total synthesis of IL-15 using a versatile solubilizing strategy (RST-2.0), which enables the preparation and ligation of aggregation-prone segments while being readily removable during folding. Remarkably, this strategy is fully compatible with glycopeptide synthesis, allowing for the synthesis of homogeneously N79-glycosylated IL-15. The effectiveness of RST-2.0 was further demonstrated through the efficient synthesis of wild-type and azide-labeled Interleukin-2 (IL-2) analogs. Moreover, the bioactivity of IL-15 and IL-2 analogs was validated by CTLL-2 proliferation assays and microscale thermophoresis (MST). This work provides a de novo synthesis approach to elucidate the role of N-glycosylation on IL-15-mediated immune regulation and lays the foundation for developing next-generation cancer immunotherapies based on synthetic IL-15 variants.

Indexed as

Interleukin-15Interleukin-2GlycosylationHumansHydrophobic and Hydrophilic InteractionsProtein AggregatesSolubilityInterleukin-15Interleukin-2Protein Aggregatesaggregationchemical synthesispeptidesprotein

Identifiers

PMID42179100
PMCPMC13383028

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.